98%
921
2 minutes
20
Diagnostic criterion for pneumonia includes clinical data and bronchoalveolar lavage cultures (BALCx) to identify pathogens. Although ~60% of BALCx are negative, there may be reluctance to discontinue antibiotics, leading to prolonged antibiotic use (PAU). The purpose of this study is to compare outcomes of subjects with negative BALCx with PAU versus without prolonged antibiotic use (nPAU). A retrospective cohort study was conducted including subjects admitted to the intensive care unit (ICU), with suspected pneumonia, and negative BALCx. Data were compared based on length of exposure to antibiotics, PAU (antibiotics >4 days) versus nPAU (antibiotics <4 days). A total of 128 subjects were included, 57 in the PAU group and 71 in the nPAU group. Baseline demographics were similar between groups. Severity of illness measured by multiple organ dysfunction scores at time of bronchoalveolar lavage (BAL) collection to final result showed a statistically significant decrease in the PAU group but not in the nPAU group. No differences were found in ICU days, ventilator-free days, or mortality; however, length of stay was longer for PAU (23 vs. 17, = .04). In the PAU group, there were fewer BALCx results of "no growth" (23% vs. 45%, = .04), more positive gram stains (83% vs. 60%, = .01) and more positive non-BALCx (40% vs. 14%, = .01). In a multivariate analysis, factors associated with PAU were positive BAL gram stains (adjusted odds ratio [aOR] 3.1, = .037) and positive non-BALCx (aOR 4.7, = .002). For subjects with suspected pneumonia and negative BALCx, positive non-BALCx and positive BALCx gram stain influenced the length of exposure of antibiotics.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554588 | PMC |
http://dx.doi.org/10.1177/0018578720918548 | DOI Listing |
Infection
September 2025
Institute of Primary Care, University of Zurich and University Hospital Zurich, Pestalozzistrasse 24, Zurich, 8091, Switzerland.
Purpose: Antibiotic-sparing treatment (ASPT) strategies, such as delayed prescribing and symptomatic treatment, are promising to reduce antimicrobial consumption (AMC) in patients with uncomplicated urinary tract infections (uUTI). The aim of this scoping review was to identify literature reporting on factors that may act as barriers and facilitators to the use of ASPT in order to improve implementation.
Methods: MEDLINE (Ovid), Embase, the Cochrane Database, Google Scholar, Proquest Dissertations and Theses, the Clinical Trials Gov Registry and the ICTRP WHO Registry were searched for evidence of health care professionals and/or patients exposed to ASPT in the context of uUTI.
Int J Nanomedicine
September 2025
Department of Pharmaceutics and Pharmaceutical Technology, Universitas Padjadjaran, Sumedang, West Java, 45363, Indonesia.
Background: Candidiasis, predominantly caused by , poses a significant global health challenge, especially in tropical regions. Nystatin is a potent antifungal agent that is hindered by its low solubility and permeability, limiting its clinical efficacy.
Methods: This study aimed to investigate the potential of a layer-by-layer (LBL) coating system, employing chitosan and alginate, to improve the stability, entrapment efficiency (%EE), and antifungal efficacy of nystatin-loaded liposomes against Candida albicans.
J Mater Chem B
September 2025
State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan University, Guangzhou 511436, China.
Globally, new antibiotic development lags behind the rapid evolution of antibiotic-resistant bacteria. Given the extensive research and development cycles, high costs, and risks associated with new pharmaceuticals, exploring alternatives to conventional antibiotics and enhancing their efficacy and safety is a promising strategy for addressing challenges in the post-antibiotic era. Previous studies have shown that antimicrobial peptides/peptidomimetics (AMPs) primarily use a membrane-disruption mechanism distinct from conventional antibiotics to exert bactericidal effects.
View Article and Find Full Text PDFBMC Pulm Med
September 2025
Division of Cellular Pneumology, Priority Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, 23845, Germany.
Background: Volatile anesthetics are gaining recognition for their benefits in long-term sedation of mechanically ventilated patients with bacterial pneumonia and acute respiratory distress syndrome. In addition to their sedative role, they also exhibit anti-bacterial and anti-inflammatory properties, though the mechanisms behind these effects remain only partially understood. In vitro studies examining the prolonged impact of volatile anesthetics on bacterial growth, inflammatory cytokine response, and surfactant proteins - key to maintaining lung homeostasis - are still lacking.
View Article and Find Full Text PDFNeurosurgery
September 2025
Department of Anesthesiology and Critical Care, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.
Background And Objectives: Postoperative central nervous system infections remain a major complication following craniotomy, with reported incidence ranging from 2.2% to 9.6%.
View Article and Find Full Text PDF